Has the best route of administration for epoetin been established?-Reference-Cited by-同舟云学术

Has the best route of administration for epoetin been established?

Published:2002 Issue: Volume: Page:15-28
ISSN:
Container-title:Renal Anemia
language:
Short-container-title:

Author:

Besarab Anatole,Schmidt Rebecca

Publisher

Springer Netherlands

Link

http://link.springer.com/content/pdf/10.1007/978-94-015-9998-6_3

Reference39 articles.

1. Kaufman JS, Reda DJ, Fye CI, Goldfarb DS, Henderson WG, Kleinmann JG, Vaamonde CA. Subcutaneous compared to intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemo-dialysis patients. N Engl J Med .1998;339:578–83.

2. National Kidney Foundation-Dialysis Outcomes Quality Initiative. NKF-DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis. 1997;30:S192–240.

3. McClellan WM, Frankenfield DL, Wish JB, Rocco MV, Johnson CA, Owen WF, for the End-Stage Renal Disease Core Indicators Work Group. Subcutaneous erythropoietin results in lower dose and equivalent hematocrit levels among adult hemodialysis patients: results from the 1998 end-stage renal disease core indicators project. Am J Kidney Dis. 2001;37(5);E36.

4. Jacobs C, Horl WH, Macdougall IC, Valderrabano F, Parrondo I, Abraham IL, Segner A. European best practice guidelines 9–13 anaemia management. Nephrol Dial Transplantation. 2000;15(supplement 4):33–42.

5. Albitar S, Meulders O, Hammoud H, Soutif C, Bouvier P, Pollini J. Sub-cutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplantation. 1995;l()(supplement 6):40–3.